Max Rady College of Medicine
Room ON2058, 675 McDermot Avenue
University of Manitoba
Winnipeg, Manitoba R3E 0V9
Leukemia and BMT
Dr. Paulson leads multiple national leukemia and stem cell transplant registries and is the primary investigator on an international prospective clinical trial. He is the site primary investigator on multiple academic and industry sponsored clinical trials.
Dr. Kristjan Paulson is an assistant professor of internal medicine at the Max Rady College of Medicine, University of Manitoba.
He is a hematologist with additional training in the fields of acute leukemia and blood and marrow transplantation. He provides clinical services within the Leukemia and Blood and Marrow Transplant Disease Site Groups.
He is the primary investigator and scientific director for the Canadian Blood and Marrow Transplant Group Registry, a clinical outcomes database of over 10,000 Canadians who have undergone stem cell transplantation.
He is also a co-investigator on the Canadian National Transplant Research Program, a CIHR-funded research network and leads the transplant registry and biostatistical cores.
Dr. Paulson is currently the co-principal investigator of an 11-centre Canadian/Australian phase III randomized trial, in the evaluation of cyclophosphamide as graft versus host disease prophylaxis in matched donors.
He is leading the development of a Canadian acute leukemia registry and serves on the board of the Canadian Acute Leukemia Study Group.
He was the inaugural registry Chair of the Canadian National Transplant Research Program, a CIHR-funded research network.
He is currently the president of Cell Therapy Transplant Canada (CTTC), the professional society of the Canadian stem cell transplant community (the first Manitoban to assume this role).
A major initiative of his presidency has been the active role the CTTC has played in bringing novel cell therapies such as Chimeric Antigen Receptor T-Cells (CAR-T) to Canada.
He chaired a Canadian workshop on the implementation of advanced cell therapies (such as CAR-T) in 2019.